Programmed Necrosis and its Role in Management of Breast Cancer
Publication date: Available online 17 September 2019Source: Pathology - Research and PracticeAuthor(s): Banita Thakur, Yashwant Kumar, Alka BhatiaAbstractBreast cancer is one of the major causes of cancer related deaths in women worldwide. A major factor responsible for treatment failure in breast cancer is the development of resistance to commonly used chemotherapeutic drugs leading to disease relapse. Several studies have shown dysregulation of molecular machinery of apoptosis, the major programmed cell death pathway in breast malignancies. Thus, there is an unmet need to search for an alternative cell death pathway which can work when apoptosis is compromised. Necroptosis or programmed necrosis is a relatively recently described entity which has attracted attention in this context. Classically, even in physiological conditions necroptosis is found to act if apoptosis is not functional due to some reason. Recently, more and more studies are being conducted in different malignancies to explore the possibility and utility of inducing cell death by necroptosis. The present review describes the key molecular players involved in necroptotic pathway and their status in breast cancer. In addition, the research done to utilize this pathway for treatment of breast cancer has also been highlighted.
ConclusionsThis work has demonstrated a significant correlation between the degree of lesion enhancement in CESM and malignancy. Quantitative analysis of enhancement levels in CESM can distinguish between invasive cancers and benign or in situ lesions.Key Points• There is a possibility of quantitative assessment of contrast enhancement in CESM.• Correlation between quantitative assessment of contrast enhancement in CESM and histopathology was observed.
This study aims to report a literature review considering epidemiological and molecular mechanisms that correlate PCOS and breast cancer, as well as the influence of PCOS treatment on the incidence of breast cancer.Epidemiological studies failed to adjust potential variables that affect the risk and have thus provided inconclusive results. Molecular effects of androgenic pathways in breast cancer have been studied and androgens seem to have an inhibitory effect on mammary epithelial proliferation. However, increased bioavailable androgens were associated with recurrence of breast cancer due to conversion to oestrogens. Sex...
Breast cancer in men accounts for about 1% of all breast cancer cases – but the mortality rate is higher for men
Publication date: Available online 15 October 2019Source: Hematology/Oncology Clinics of North AmericaAuthor(s): Lior Z. Braunstein, Jennifer R. Bellon
Publication date: Available online 15 October 2019Source: International Journal of PharmaceuticsAuthor(s): Wei Zheng, Cong Wang, Ruihong Ding, Yahong Huang, Yanyi Li, Yan LuAbstractTriptolide (TP), a diterpenoid triepoxide that is extracted from the plant Tripterygium wilfordii, has been found to be quite effective for treating many malignant tumors. Although TP was initially considered to be a promising chemotherapeutic agent, its poor solubility and high toxicity limited its potential clinical application. Consequently, we synthesized nanoformulated TP coated with hyaluronic acid (HA) for application in treating breast c...
field Jacqueline A. Wilce Grb7 is an adapter protein, overexpressed in HER2+ve breast and other cancers, and identified as a therapeutic target. Grb7 promotes both proliferative and migratory cellular pathways through interaction of its SH2 domain with upstream binding partners including HER2, SHC, and FAK. Here we present the evaluation of a series of monocyclic and bicyclic peptide inhibitors that have been developed to specifically and potently target the Grb7 SH2-domain. All peptides tested were found to inhibit signaling in both ERK and AKT pathways in SKBR-3 and MDA-MB-231 cell lines. Proliferation, migration, ...
GE Healthcare and group purchasing organization Premier have agreed to develop...Read more on AuntMinnie.comRelated Reading: GE lands 10-year deal with NYC Health + Hospitals GE, Theragnostics partner on PSMA agent GE, partners to develop PET tracers GE inks deal for imaging antibodies FDA clears GE's AI for chest x-ray review
ConclusionsThe results of this study showed that lung volume changes were not a cause for concern in breast cancer patients. There are three reasons to support this conclusion. Lung volume changes and percentage reductions in LVP for each Gy increase of MLD and each percentage increase of V20 in each lobe were small; patients were asymptomatic during the follow-up period; and LVP showed partial improvements after 6 months.
ConclusionUsing robust optimization for skin flash in breast IMRT planning is feasible. Further investigation is warranted to confirm the clinical effectiveness of this novel approach.